Oncology Central

The next generation of novel therapies for the management of relapsed multiple myeloma


The advent of various novel therapies such as immunomodulators and proteasome inhibitors has transformed the treatment paradigm for patients with multiple myeloma (MM). As a result, the overall survival has improved dramatically over the last decade. Despite these advances, MM remains mostly incurable and most patients experience disease relapse after enjoying a period of disease control or remission.

To view restricted content, please:

Leave A Comment